Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Psychosocial interventions intended primarily to reduce antipsychotic use vs (Optimised) usual care

Adverse events · Residents of nursing homes and other long-term care facilities

1 finding from 1 review

Psychosocial interventions for reducing antipsychotic medication in care home residents 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3 participants
High

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone

Adverse events · proliferative diabetic retinopathy

1 finding from 1 review

Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1070 participants
Very low

Exercise therapy vs Placebo (sham/placebo device)

Adverse events · acute non‐specific LBP

The review found no eligible studies for this question.

1 finding from 1 review

Exercise therapy for treatment of acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise therapy vs no treatment

Adverse events · acute non‐specific LBP

The review found no eligible studies for this question.

1 finding from 1 review

Exercise therapy for treatment of acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

McKenzie therapy vs manual therapy

Adverse events · patients with non‐specific acute and subacute low back pain

The review found no eligible studies for this question.

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

McKenzie therapy vs other interventions

Adverse events · patients with non‐specific acute and subacute low back pain

The review found no eligible studies for this question.

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

McKenzie therapy vs minimal intervention

Adverse events · patients with non‐specific acute and subacute low back pain

The review found no eligible studies for this question.

1 finding from 1 review

The McKenzie method for (sub)acute non‐specific low back pain 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Low

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 115 participants
Very low